Acadia Pharmaceuticals (ACAD) Non Operating Income (2018 - 2026)

Acadia Pharmaceuticals' Non Operating Income history runs 9 years deep, the most recent figure standing at $542000.0 for Q1 2026.

• In Q1 2026, Non Operating Income fell 7.82% year-over-year to $542000.0; the TTM figure through Mar 2026 stood at $2.3 million (up 117.33% YoY), while the FY2025 annual figure was $2.4 million, up 117.29% from the prior year.
• Non Operating Income was $542000.0 for Q1 2026 at Acadia Pharmaceuticals, down from $596000.0 in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $4.8 million in Q1 2023 to a low of -$15.0 million in Q4 2024.
• Historically, Non Operating Income has averaged -$134437.5 across 5 years, with a median of $582000.0 in 2024.
• The sharpest annual moves came in 2022 and 2023: Non Operating Income sank 379.21% in 2022, then soared 1325.0% in 2023.
• A 5-year view of Non Operating Income shows it stood at $1.5 million in 2022, then fell by 2.27% to $1.5 million in 2023, then slumped by 1092.24% to -$15.0 million in 2024, then soared by 103.98% to $596000.0 in 2025, then dropped by 9.06% to $542000.0 in 2026.
• The last three Non Operating Income figures came in at $542000.0 (Q1 2026), $596000.0 (Q4 2025), and $593000.0 (Q3 2025), per Business Quant data.